发明名称 MetAP-2 inhibitor polymersomes for therapeutic administration
摘要 Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
申请公布号 US9272050(B2) 申请公布日期 2016.03.01
申请号 US201414495725 申请日期 2014.09.24
申请人 CHILDREN'S MEDICAL CENTER CORPORATION 发明人 Benny-Ratsaby Ofra;D'Amato Robert;Folkman Judah
分类号 A61K31/77;A61K47/48;A61K31/336 主分类号 A61K31/77
代理机构 Nixon Peabody LLP 代理人 Nixon Peabody LLP ;Resnick David S.;FitzGerald Mark J.
主权项 1. A composition formulated for oral administration comprising a fumagillol derivative having anti-proliferative activity, wherein said fumagillol derivative is covalently linked to a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety, wherein said block copolymer is a diblock copolymer comprising a PEG-PLA diblock copolymer having hydrophilic PEG and hydrophobic PLA moieties, and wherein said fumagillol derivative is covalently linked with the hydrophobic moiety of said block copolymer.
地址 Boston MA US